This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Apellis Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Apellis Pharmaceuticals CEO'su Cedric Francois, Sep2009 tarihinde atandı, in görev süresi 16.67 yıldır. in toplam yıllık tazminatı $ 13.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.2% maaş ve 93.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.14% ine doğrudan sahiptir ve bu hisseler $ 59.66M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 10.8 yıldır.
Anahtar bilgiler
Cedric Francois
İcra Kurulu Başkanı
US$13.3m
Toplam tazminat
| CEO maaş yüzdesi | 6.16% |
| CEO görev süresi | 16.7yrs |
| CEO sahipliği | 1.1% |
| Yönetim ortalama görev süresi | 4.8yrs |
| Yönetim Kurulu ortalama görev süresi | 10.8yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Apr 29
APLS: Biogen Deal Terms And Mixed Ratings Will Guide Future Repricing
Analysts have raised the fair value estimate for Apellis Pharmaceuticals to about $40.93, citing Street research that combines several recent price target increases with a series of downgrades following Biogen's acquisition announcement, along with updated views on long-term P/E assumptions and risk. Analyst Commentary Street research around the Biogen acquisition announcement shows a split in how analysts are framing Apellis Pharmaceuticals, with some highlighting upside to long-term value and others focusing on execution and pricing risks.Anlatı Güncellemesi • Apr 15
APLS: Balanced Biogen Deal And Mixed Ratings Will Shape Future Repricing
Apellis Pharmaceuticals' updated fair value estimate has shifted from $35.71 to $39.93 per share as analysts factor in higher long run P/E assumptions near 42x, alongside recent price target changes that include several upgrades, downgrades and target raises from firms such as Mizuho, JPMorgan, Morgan Stanley and RBC Capital. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split tape, with several firms lifting price targets while a cluster of downgrades points to fresh execution and valuation questions.Anlatı Güncellemesi • Apr 01
APLS: Syfovre Outlook And Downgrade Wave Will Limit Future Repricing
Analysts now see fair value for Apellis Pharmaceuticals at about $35.71 per share, up from roughly $33.60, reflecting updated views on revenue growth, margins, discount rates, and a somewhat higher future P/E multiple after a mix of recent price target raises, initiations, and downgrades across the Street. Analyst Commentary Street research on Apellis Pharmaceuticals reflects a mixed but engaged view, with both bullish and bearish analysts adjusting targets, ratings, and coverage in response to recent reports and product updates.Seeking Alpha • Mar 31
Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing
Summary Biogen acquires Apellis for $41/share, a 140% premium, aiming to leverage Apellis’ nephrology sales force and product portfolio. Syfovre’s safety issues have stabilized, but its commercial prospects remain limited versus Astellas’ Izervay, justifying Biogen’s cautious CVR structure. Biogen’s acquisition thesis hinges on felzartamab’s potential in complement-mediated rare diseases, especially AMR, targeting $800M+ peak sales. I downgrade APLS to 'Sell' post-acquisition, as upside is realized; BIIB remains a 'Hold' given execution risk and dependence on felzartamab’s success. Read the full article on Seeking AlphaAnlatı Güncellemesi • Mar 18
APLS: Kidney Disease Launch And Index Adds Will Drive Future Repricing
Narrative Update on Apellis Pharmaceuticals The updated analyst price target framework now aligns with Street research that has recently adjusted Apellis price objectives in a roughly $18 to $44 range, with analysts pointing to demand trends for Syfovre and Empaveli, mixed views on growth beyond the current Q4 reporting period, and differing assumptions for revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Apellis Pharmaceuticals presents a mixed picture, with price targets spanning roughly US$18 to US$44 and a range of views on execution, product demand and future growth.
Anlatı Güncellemesi • Mar 04
APLS: Future C3G Launch Execution Will Drive Bullish Re Rating Potential
Apellis Pharmaceuticals' updated analyst price targets cluster around the high teens to mid $40s, with modest adjustments up and down as analysts factor in the Q4 update, expectations for flat Syfovre pricing into FY26, progress in the C3G launch, and slightly revised assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Apellis Pharmaceuticals reflects a mixed but generally constructive stance, with price targets spanning from the high teens into the mid $40s and a blend of Neutral, Buy, and Overweight views.Anlatı Güncellemesi • Feb 17
APLS: Kidney Disease Launch And Index Adds Will Support Future Repricing
Analysts have nudged their consolidated price target and fair value framework for Apellis slightly higher to $33.95, reflecting a blend of cautious optimism from fresh Neutral initiations and upgrades, along with mixed target revisions following the recent Q4 pre-announcement and C3G launch commentary. Analyst Commentary Recent research has focused on how Apellis is executing around its Q4 pre announcement and the early C3G launch, and what that means for valuation and risk.Anlatı Güncellemesi • Feb 03
APLS: Kidney Disease Launch And Index Additions Will Support Future Share Recovery
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about US$1.44 per share, reflecting more cautious assumptions on revenue growth and profit margins, even as some recent research updates point to steady product launches and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on Apellis Pharmaceuticals shows a split view, with some analysts focusing on product execution and others emphasizing revenue uncertainty and guidance gaps.Anlatı Güncellemesi • Jan 20
APLS: Future C3G Renal Uptake Will Drive Bullish Re Rating Potential
Analysts have slightly increased their overall price expectations for Apellis, with recent Street targets clustering in a US$27 to US$45 range, as they balance cautious views on Syfovre revenue trends and guidance gaps against ongoing uptake in C3G and related renal indications. Analyst Commentary Recent Street research shows a mix of caution and optimism on Apellis, with several bullish analysts highlighting areas where they see the story improving around execution, revenue mix and potential upside to current expectations.Anlatı Güncellemesi • Jan 05
APLS: Future Renal Indication Execution Will Drive Bullish Re Rating Potential
Analysts have trimmed their price targets for Apellis Pharmaceuticals, with recent cuts to US$45 and US$27. These moves reflect concerns about "flattish" Syfovre revenue and uncertainty around Empaveli's early renal indications, even as long term fair value assumptions and projected revenue growth in some models remain unchanged.Anlatı Güncellemesi • Dec 14
APLS: Future Kidney Indication Uptake Will Drive Bullish Re-Rating Potential
Analysts have trimmed their average price target on Apellis Pharmaceuticals by about $5 per share. They cite higher perceived risk, slower expected revenue growth from Syfovre and Empaveli, and somewhat lower long term margin assumptions, although several covering firms remain generally supportive.Anlatı Güncellemesi • Nov 29
APLS: Kidney Disease Indication Launch Will Drive Share Price Recovery Ahead
Analysts have modestly lowered their average price target for Apellis Pharmaceuticals. They cite cautious outlooks on revenue growth and recent segment performance, with new targets ranging from $27 to $45 per share compared to prior targets up to $52.Anlatı Güncellemesi • Nov 15
APLS: Future Revenue From Kidney Disease Expansion Will Drive Shares Higher
Analysts have modestly lowered their fair value estimate for Apellis Pharmaceuticals from approximately $36.50 to $35.39 per share. This adjustment is due to concerns over slower revenue growth and contracting profit margins following recent company updates.Anlatı Güncellemesi • Oct 31
APLS: Uptake In Rare Kidney Disease Segment Will Drive Future Upside
Analysts have lowered their average price target for Apellis Pharmaceuticals, reducing it by nearly $1 to $36.50. This adjustment reflects moderating revenue growth forecasts and a higher discount rate, although expectations for profit margin have marginally improved.Anlatı Güncellemesi • Sep 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
Analyst price targets for Apellis Pharmaceuticals have edged lower to $37.47 as positive signals from Syfovre sales and pipeline opportunities are tempered by concerns over limited revenue guidance and commercial ramp uncertainties. Analyst Commentary Bullish analysts cite stabilization in the Geographic Atrophy (GA) market and optimism around the ongoing launches in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).Anlatı Güncellemesi • Aug 27
FDA Label Expansion And SYFOVRE Will Unlock Future Value
The consensus analyst price target for Apellis Pharmaceuticals has risen modestly to $38.56, reflecting improving sentiment from stabilizing Geographic Atrophy market dynamics, continued Syfovre injection growth, and upside potential from Empaveli expansions, despite some concerns over Syfovre sales guidance and a possibly slower Empaveli ramp. Analyst Commentary Bullish analysts point to stabilizing Geographic Atrophy market dynamics and the ongoing launch initiatives in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) as a driver for upward price revisions.Analiz Makalesi • Jul 29
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Yeni Anlatı • May 02
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.Seeking Alpha • Mar 05
Apellis Pharmaceuticals: A Mixed Bag
Summary Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complicated tale around this mid-cap, but the company looks set to move to profitability with the funding it has on hand. The analyst firm community is quite mixed on the current prospects around Apellis Pharmaceuticals, however. An analysis around APLS stock follows in the paragraphs below. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$133m |
| Dec 31 2025 | US$13m | US$822k | US$22m |
| Sep 30 2025 | n/a | n/a | US$45m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$224m |
| Dec 31 2024 | US$11m | US$793k | -US$198m |
| Sep 30 2024 | n/a | n/a | -US$250m |
| Jun 30 2024 | n/a | n/a | -US$333m |
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
Tazminat ve Piyasa: Cedric 'nin toplam tazminatı ($USD 13.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 8.38M ).
Tazminat ve Kazançlar: Cedric 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Cedric Francois (53 yo)
16.7yrs
Görev süresi
US$13,342,739
Tazminat
Dr. Cedric Francois, M.D., Ph.D. is Co-Founder and Chairman of Liberate Medical, Inc. He serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and ha...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 16.7yrs | US$13.34m | 1.14% $ 59.7m | |
| CFO & Treasurer | 8.6yrs | US$4.98m | 0.084% $ 4.4m | |
| General Counsel & Secretary | 12.3yrs | US$4.73m | 0.071% $ 3.7m | |
| Chief People Officer | 1.3yrs | US$4.53m | 0% $ 0 | |
| Chief Medical Officer | 3.3yrs | US$4.62m | 0.028% $ 1.4m | |
| Co-Founder & Chief Scientific Officer | 16.7yrs | US$3.08m | 0.88% $ 46.3m | |
| VP, Corporate Controller & Chief Accounting Officer | 4.8yrs | Veri yok | 0.018% $ 959.7k | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 4yrs | Veri yok | Veri yok | |
| Chief Technical Operations Officer | no data | US$3.02m | 0.027% $ 1.4m | |
| Executive Vice President of Commercial | no data | Veri yok | Veri yok | |
| Chief Business & Strategy Officer | 3.3yrs | Veri yok | 0.090% $ 4.7m |
4.8yrs
Ortalama Görev Süresi
54.5yo
Ortalama Yaş
Deneyimli Yönetim: APLS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of AMD Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of AMD Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of AMD Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of PNH Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok | |
| Member of Pulmonology Scientific Advisory Board | 10.8yrs | Veri yok | Veri yok |
10.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim Kurulu: APLS 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.8 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/16 08:41 |
| Gün Sonu Hisse Fiyatı | 2026/05/13 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Apellis Pharmaceuticals, Inc. 27 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Ulz | Baird |
| Colleen Kusy | Baird |
| Eliana Merle | Barclays |